[1] 中华医学会感染病学分会艾滋病学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2024版)[J/CD]. 新发传染病电子杂志, 2024,9(4):68-94. [2] 郝波. HIV感染抗病毒治疗患者10年心血管疾病风险评估及影响因素[J]. 江苏预防医学, 2025,36(5):642-644. [3] EKUN O A, FASELA E O, OLADELE D A, et al.Risks of cardio-vascular diseases among highly active antiretroviral therapy (HAART) treated HIV seropositive volunteers at a treatment centre in Lagos, Nigeria[J]. Pan Afr Med J, 2021,23(38):206. [4] 中华人民共和国国务院办公厅. 中国遏制与防治艾滋病规划(2024—2030年)[J/CD]. 新发传染病电子杂志, 2025, 10(1):91-93. [5] GAMBAHAYA ET, RANA R, BAGCHI S, et al.The Role of Multimodality Imaging in HIV-Associated Cardiomyopathy[J]. Front Cardiovasc Med, 2022, 8:811593. [6] HUDSON JA, FERRAND RA, GITAU SN, et al.HIV-Associated Cardiovascular Disease Pathogenesis: An Emerging Understanding Through Imaging and Immunology[J]. Circ Res, 2024,134(11):1546-1565. [7] MENACHO K, SERAPHIM A, RAMIREZ S, et al.Myocardial Inflammation and Edema in People Living With Human Immunodeficiency Virus[J]. JACC Cardiovascular Imaging, 2020,13(5):1278-1280. [8] DAGHER A M B, LEE J, CUNNINGHAM H E, et al. Cardiac Kaposi Sarcoma Complicated by Kaposi Sarcoma Inflammatory Cytokine Syndrome: A Case Report[J]. Cureus, 2025,17(1):e76972. [9] GRADINARU A, COLITA A, MURARETU I, et al.Cardiac mass in a patient with HIV infection: A case report and literature review[J]. Exp Ther Med, 2026,31(2):1-13. [10] KHABA MC, KAMPETU MF, RANGAKA MC, et al.Primary cardiac lymphoma in HIV infected patients: A clinicopathological report of two cases[J]. Ann Med Surg (Lond), 2021,69:102757. [11] HSUE PY, WATERS DD.HIV infection and coronary heart disease: mechanisms and management[J]. Nat Rev Cardiol, 2019, 16(12):745-759. [12] OBARE LM, TEMU T, MALLAL SA, et al.Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease[J]. Circ Res, 2024,134(11):1515-1545. [13] 杨雨晴, 陆林. 与HIV感染相关的心血管疾病研究热点可视化分析[J]. 中国公共卫生管理, 2022, 38(3):372-377. [14] WHELTON SP, HABERLEN SA, ZHANG L, et al.Associations between HIV serostatus and coronary artery plaque volume progression[J]. AIDS, 2025,39(10):1413. [15] OGYEFO IN, OBESE V, NORMAN BR, et al.Prevalence and patterns of echocardiographic abnormalities among people living with HIV on anti-retroviral therapy in Kumasi, Ghana[J]. BMC Cardiovasc Disord, 2024,24(1): 453. [16] WOLDEYES E, FISSEHA H, MULATU HA, et al.Echocardiographic findings and associated factors in HIV-infected patients at a tertiary hospital in Ethiopia[J]. Medicine, 2022, 101(33):e30081. [17] MIREA O, MANESCU M, IORDACHE S, et al.Echocardiography Assessment of Cardiac Function in Adults Living with HIV: A Speckle Tracking Study in the Era of Antiretroviral Therapy[J]. J Clin Med, 2022,11(13):3792. [18] LIAO CT, TOH HS, CHANG WT, et al.Assessment of subclinical cardiac dysfunction by speckle-tracking echocardiography among people living with human immunodeficiency virus[J]. Front Cardiovasc Med, 2023,10:1200418. [19] KEYVANFAR A, NAJAFIARAB H, RAMEZANI S, et al.Cardiac tamponade in people living with HIV: a systematic review of case reports and case series[J]. BMC Infect Dis, 2024,24(1):882. [20] GARCÍA-OTERO L, LÓPEZ M, GUITART-MAMPEL M, et al. Cardiac and mitochondrial function in HIV-uninfected fetuses exposed to antiretroviral treatment[J]. PLOS ONE, 2019,14(3):e0213279. [21] HESELTINE T, HUGHES E, MATTEW J, et al.The association of epicardial adipose tissue volume and density with coronary calcium in HIV-positive and HIV-negative patients[J]. J Infect, 2023,86(4):376-384. [22] PEREIRA B, MAZZITELLI M, MILINKOVIC A, et al.Short Communication: Predictive Value of HIV-Related Versus Traditional Risk Factors for Coronary Atherosclerosis in People Aging with HIV[J]. AIDS Res Hum Retroviruses, 2022,38(2):80-86. [23] SHAIKH K, BHONDOEKHAN F, HABERLEN S, et al.Coronary artery plaque progression and cardiovascular risk scores in men with and without HIV-infection[J]. AIDS, 2022,36(2):215. [24] LU MT, RIBAUDO H, FOLDYNA B, et al.Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers in HIV: Mechanistic Substudy of the REPRIEVE Randomized Clinical Trial[J]. JAMA Cardiology, 2024,9(4):323-334. [25] ROYSTON L, ISNARD S, PERRIN N, et al.Growth differentiation factor-15 as a biomarker of atherosclerotic coronary plaque: Value in people living with and without HIV[J]. Front Cardiovasc Med, 2022, 9:964650. [26] ROBBERTSE PPS, DOUBELL AF, LOMBARD CJ, et al.Evolution of myocardial oedema and fibrosis in HIV infected persons after the initiation of antiretroviral therapy: a prospective cardiovascular magnetic resonance study[J]. J Cardiovasc Magn Reson, 2022,24(1):72. [27] YAN C, LI R, GUO X, et al.Cardiac Involvement in Human Immunodeficiency Virus Infected Patients: An Observational Cardiac Magnetic Resonance Study[J]. Front Cardiovasc Med, 2021, 8:756162. [28] PETERSON TE, LANDON C, HABERLEN SA, et al.Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV[J]. BMC Cardiovasc Disord, 2022, 22(1): 393. [29] MUTENGO KH, LIMA BB, MUTALE W, et al.The influence of HIV infection on myocardial fibrosis diagnosed by cardiac magnetic resonance imaging in adults: a systematic review and meta-analysis of observation studies[J]. Front Cardiovasc Med, 2025,12:1534533. [30] SHULDINER SR, WONG LY, PETERSON TE, et al. Myocardial Fibrosis Among Antiretroviral Therapy-Treated Persons With Human Immunodeficiency Virus in South Africa[J]. Open Forum Infect Dis, 2021,8(1):ofaa600. [31] DE LEUW P, ARENDT CT, HABERL AE, et al.Myocardial Fibrosis and Inflammation by CMR Predict Cardiovascular Outcome in People Living With HIV[J]. JACC Cardiovascular Imaging, 2021,14(8):1548-1557. [32] NTUSI NAB.HIV and myocarditis[J]. Curr Opin HIV AIDS, 2017,12(6):561. [33] TAWAKOL A, NEILAN TG.Tissue Characterization With CMR and Adverse Cardiac Events Among Persons With HIV[J]. JACC Cardiovascular Imaging, 2021,14(8):1558-1560. [34] HOLLOWAY CJ, NTUSI N, SUTTIE J, et al.Comprehensive Cardiac Magnetic Resonance Imaging and Spectroscopy Reveal a High Burden of Myocardial Disease in HIV Patients[J]. Circulation, 2013,128(8):814-822. [35] GARCIA JR, OLIVERO R, ARRIETA-ALDEA I, et al.Association between cardiovascular inflammation and alterations in immune system induced by HIV infection detected on[18F] FDG PET/MRI[J]. Rev Esp Med Nucl Imagen Mol (Engl Ed), 2024,43(5):500042. [36] MIKAIL N, SINIGAGLIA M, HYAFIL F.Could FDG-PET imaging play a role in the detection of progressing atherosclerosis in HIV-infected patients?[J]. J Nucl Cardiol, 2019,26(4):1266-1268. [37] KRISTOFFERSEN US, LEBECH AM, WIINBERG N, et al.Silent Ischemic Heart Disease and Pericardial Fat Volume in HIV-Infected Patients: A Case-Control Myocardial Perfusion Scintigraphy Study[J]. PLOS ONE, 2013,8(8):e72066. [38] TAGLIERI N, BONFIGLIOLI R, BON I, et al.Pattern of arterial inflammation and inflammatory markers in people living with HIV compared with uninfected people[J]. J Nucl Cardiol, 2022,29(4):1566-1575. [39] HENRICH TJ, HSUE PY, VANBROCKLIN H.Seeing Is Believing: Nuclear Imaging of HIV Persistence[J]. Front Immunol, 2019,10:2077. [40] ALOWAIS SA, ALGHAMDI SS, ALSUHEBANY N, et al.Revolutionizing healthcare: the role of artificial intelligence in clinical practice[J]. BMC Med Educ, 2023,23(1):689. [41] MARCUS JL, SEWELL WC, BALZER LB, et al.Artificial Intelligence and Machine Learning for HIV Prevention: Emerging Approaches to Ending the Epidemic[J]. Curr HIV/AIDS Rep, 2020,17(3):171-179. [42] WANG G, WEI W, JIANG J, et al.Application of a long short-term memory neural network: a burgeoning method of deep learning in forecasting HIV incidence in Guangxi, China[J]. Epidemiol Infect, 2019,147:e194. [43] BALZER LB, HAVLIR DV, KAMYA MR, et al.Machine Learning to Identify Persons at High-Risk of Human Immunodeficiency Virus Acquisition in Rural Kenya and Uganda[J]. Clin Infect Dis, 2020,71(9):2326-2333. [44] LI X, XU X, WANG J, et al.Study on Prediction Model of HIV Incidence Based on GRU Neural Network Optimized by MHPSO[J]. IEEE Access, 2020,8:49574-49583. [45] SAH AK, ELSHAIKH RH, SHALABI MG, et al.Role of Artificial Intelligence and Personalized Medicine in Enhancing HIV Management and Treatment Outcomes[J]. Life (Basel), 2025,15(5):745. [46] 柴程良, 何林, 蒋健敏. 人工智能+数字技术:驱动艾滋病防治高质量发展的核心引擎[J]. 中国艾滋病性病, 2025,31(8):829-832. |